El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when prescribed to treat sleep apnea. The cost of prescription drugs is set to climb in 2025 and beyond, according to a report from the investment bank TD Cowen. And President-elect Donald Trump’s plan to impose tariffs on Denmark could drive up the already expensive cost of one of America’s fastest-growing obsessions: weight-loss drugs.
Check out those stories and more pharmaceutical news highlights from this week.